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Abstract
In vitro, cellular immortalization and transformation define a model for multistep carcinogenesis and current ongoing
challenges include the identification of specific molecular events associated with steps along this oncogenic pathway. Here,
using NIH3T3 cells, we identified transcriptionally related events associated with the expression of Polyomavirus Large-T
antigen (PyLT), a potent viral oncogene. We propose that a subset of these alterations in gene expression may be related to
the early events that contribute to carcinogenesis. The proposed tumor suppressor Necdin, known to be regulated by p53,
was within a group of genes that was consistently upregulated in the presence of PyLT. While Necdin is induced following
p53 activation with different genotoxic stresses, Necdin induction by PyLT did not involve p53 activation or the Rb-binding
site of PyLT. Necdin depletion by shRNA conferred a proliferative advantage to NIH3T3 and PyLT-expressing NIH3T3 (NIHLT)
cells. In contrast, our results demonstrate that although overexpression of Necdin induced a growth arrest in NIH3T3 and
NIHLT cells, a growing population rapidly emerged from these arrested cells. This population no longer showed significant
proliferation defects despite high Necdin expression. Moreover, we established that Necdin is a negative regulator of p53-
mediated growth arrest induced by nutlin-3, suggesting that Necdin upregulation could contribute to the bypass of a p53-
response in p53 wild type tumors. To support this, we characterized Necdin expression in low malignant potential ovarian
cancer (LMP) where p53 mutations rarely occur. Elevated levels of Necdin expression were observed in LMP when compared
to aggressive serous ovarian cancers. We propose that in some contexts, the constitutive expression of Necdin could
contribute to cancer promotion by delaying appropriate p53 responses and potentially promote genomic instability.
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Introduction
Carcinogenesis is a multistep process defined by uncontrolled
cell growth and neoplastic progression leading to invasive tumors
and metastasis. Cancer progression models dictate that normal
cells undergo a variety of genetic/epigenetic alterations which can
be summarized in vitro by two major phenotypic changes: im-
mortalization and transformation. Normal cells need to overcome
cell cycle checkpoints and their limited division potential to
achieve immortalization. Interlaced with this process, additional
events contribute to cellular transformation and move cells toward
the complete neoplastic phenotype [1]. Human lung and colon
cancers, genetically altered mice, mouse and human cell culture
models, have all been extensively used to support the multistep
progression model [2,3,4].
Normal human epithelial or fibroblast cell transformation can
be obtained with the sequential expression of a series of oncogenes,
often including the viral proteins SV40LT (simian virus 40 Large-
T antigen) or adenovirus early protein E1A [5,6]. Some E1A
domains conserved in SV40LT, including the CR1/CR2 Rb
family (pRb’s) binding domains and the p300/400-binding pocket
are absolutely required for this transformation process [7]. Despite
the importance of these domains, the characterization of other
viral oncogenic domains involved in transformation remains in-
complete and additional activities could contribute to the
carcinogenesis process.
Polyomavirus (Py), an oncogenic member of the papovaviruses,
causes tumors in rodents and transforms primary cells in culture
[8]. In Py-induced carcinogenesis, Large-T antigen (PyLT) is
responsible for inappropriate cell cycle promotion and immortal-
ization of mouse primary cells in culture [9,10]. This ability is
mediated principally through the binding and inactivation of
pRb’s by the CR1/CR2 amino-terminal domains [11,12]. PyLT
genetically and functionally shares extensive homology with the
closely related SV40LT, although critical differences exist. As an
example, while both proteins can bind p300 and inactivate the
pRb family of tumor suppressors, only SV40LT can bind and
inactivate p53 [13]. Functionally, SV40LT is a dual oncogene able
to immortalize and transform primary rodent cells as a single event
while PyLT appears limited to immortalization in vitro [14]. Thus,
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useful in studying different aspects of oncogenesis.
Congruent with its in vitro activity, PyLT drives tumor formation
when expressed under various promoters in transgenic mouse
models, but the lower frequency and longer latency suggest a
requirement for additional secondary events [15,16,17]. While
PyLT alone cannot transform cells in culture, it can confer
resistance to growth arrest in low serum condition [10] and protect
cells against Fas and TNF-a induced apoptosis [18]. This ability to
evade apoptotic signals could potentially promote growth and allow
cells to evade cellular-mediated immunity; important events in
multistep carcinogenesis [2,19,20]. Moreover, while PyLT does not
bind p53 directly, it has the ability to overcome some effects of this
master tumor suppressor, notably p53-induced cell cycle arrest
[21,22,23]. Finally, all E1A domains known to be essential to
human cell transformation are not only conserved in SV40LT but
arealsofound inPyLT [7]. Based on this evidence, we hypothesized
that, in addition to its immortalizing activity, PyLT also modulates
important functions in early mouse cell transformation.
Here, we present a strategy where PyLT induced immortaliza-
tion-independent events can be revealed using NIH3T3 immortal
mouse embryonic fibroblasts which already harbor immortaliza-
tion-associated events that have occurred prior to PyLT
introduction. Using gene expression microarray analysis, we
identified Necdin among a set of genes that were consistently
upregulated following PyLT expression in NIH3T3 cells. Necdin
was first identified as a neuronal differentiation marker associated
with growth arrest [24,25,26], but has since been found in several
normal tissues [27,28,29,30,31]. Necdin interacts with the viral
oncoproteins SV40LT and E1A [32] and is functionally similar to
pRb as it can promote growth arrest by interacting with E2F1 to
repress its transcriptional activity [32,33]. In accordance with this
function, Necdin overexpression shows growth inhibitory proper-
ties in NIH3T3 and SaOS cell lines [26,32]. However, it is also
expressed in myogenic precursors that have a high proliferating
potential [34]. Necdin is a p53 target gene and physically interacts
with the p53 protein product suggesting a functional relationship
[35,36]. Furthermore, the expression of Necdin can protect cells
from apoptosis in different models [29,33,34,37,38,39], including
p53-induced apoptosis [35]. Therefore we hypothesize that during
carcinogenesis, and depending on the cellular context, Necdin
possesses opposing functions and may act as a tumor suppressor
based on its similarity with pRb proteins, or as an oncogene
through its capacity to inhibit apoptosis and p53-dependent tumor
suppressive cell fates.
Results reported here support this dual functionality for Necdin.
We show that despite the growth suppressive functions of Necdin, it
was possible to derive growing cell populations expressing con-
stitutively high levels of Necdin. These high levels of Necdin
interfered with p53 activity and contributed to an ineffective growth
arrest in response to stress. Overall, we provide evidence suggesting
that upregulation of Necdin expression could provide advantages
for p53 wild type cells during early carcinogenesis through its ability
to decrease signaling from p53 pathways. Interestingly, we found
higher Necdin expression to be associated with low malignancy
potential (LMP) ovarian tumors, where p53 mutations are rare,
compared to high grade invasive ovarian cancers (TOV).
Results
Gene statement mapping of PyLT expressing mouse
fibroblasts
NIH3T3 mouse fibroblasts were transfected with a PyLT
expression plasmid and the selected clones were assessed for stable
PyLT expression at the mRNA and protein level (Figure 1, Figure
S1A). Selected clones were used for microarray analysis comparing
PyLT-expressing clones to a second group composed of parental
NIH3T3 cells as well as clones that did not express a detectable
amount of PyLT. A variation cut-off set to .1.5-fold with a P
value of $0.02 generated 194 candidate genes significantly
modulated by PyLT, composed of 160 upregulated and 34
downregulated genes (Table S1). To refine candidate selection, we
imposed a further selection criteria on the 194 genes selected in the
primary analysis based on the observation that genes displaying
co-transcriptional regulation often interact by functional relation-
ships [40]. Levels of PyLT were correlated to the amplitude of
fold-change expression (either up- or down-regulation) which
identified 26 candidate genes whose expression varied propor-
tionally to PyLT (Table S2). As an example, note the correlation
between the variation in Necdin gene expression and PyLT
(Figure S1B). These genes represented the strongest candidates
with 15 upregulated and 11 downregulated genes.
The generated data was validated by Northern blot analysis
using a selected number of genes. Expression levels on Northern
blots were compared to corresponding microarray expression
values (Figure 1, and data not shown). Gene expression variations
observed on Northern blots with full length cDNA probes were
highly similar to the data generated by the Affymetrix oli-
gonucleotide microarray for all probes and clones tested
(Figure 1). Some full-length cDNA probes generated more than
one band when using radioactive Northern blots although at least
one band of the expected molecular size closely followed the
microarray pattern (see a- s m - a c t i na n dN e c d i n ,F i g u r e1 ) .I n
addition to loaded RNA quantification, Gapd, Dohx as well as
Rsp2 showed little variation across all clones and were used as
loading controls.
Validation of a selected candidate gene, Necdin, on an
extended NIH3T3 clone set
Among all candidates identified, the gene encoding Necdin was
selected for further study. Microarray analysis showed an
upregulation of mRNA up to five-fold (T-test, P,0.001) (Table
S2 and Figure S1B). In addition, a second probe set was associated
with the Necdin gene (94811_s_at) and also revealed a 3.6-fold
upregulation, although with a P value of 0.04 (data not shown). To
further validate the microarray data, Necdin expression was
analyzed on an extended set of six NIH3T3 sub-clones and nine
independent PyLT-expressing NIH3T3 stable clones not included
in our initial analysis (Figure 2A). The higher expression levels of
Nectin observed when PyLT is expressed, as determined by
Northern blot analysis, correlated well with the data derived from
microarray analyses. Moreover, a nonradioactive Dig-labeled
probe gave only one specific band around the expected size of
1.6 kb, confirming the identity of the lower band in Figure 1 as
Necdin. Some clones with variable levels of PyLT expression were
also used to confirm that the variation measured at the RNA level
was reproduced at the protein level for Necdin (Figure 2B).
Furthermore, when we derived a new heterogeneous population of
NIH3T3 cells expressing PyLT (NIHLT), we again observed an
upregulation of Necdin expression compared to a vector-
transfected population control (NIH) (Figure 2C and Figure 3A
inset). Necdin variation could be seen as early as 72 hrs post-
transfection of PyLT. These results show that elevated Necdin
expression levels were a reproducible and constant phenotype in
PyLT-expressing NIH3T3 cells and not caused by a clonogenic
effect, thus suggesting that Necdin may be involved in some of
PyLT oncogenic functions.
PyLT/Necdin Affects p53 Response
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In order to understand the underlying mechanisms behind the
increase in Necdin expression upon PyLT expression, we used
different well-characterized mutants of important PyLT domains
(Figure 2D). Rb binding deficient LT-c/s is unable to immortalize
primary cells while LT-CKII has an increased Rb binding
capacity compared to wild-type and demonstrates twice the
immortalization potential [12]. Deletion of the zinc finger in
mutant LT-delZ does not affect Rb binding but enhances the
immortalization potential of the protein [41]. The amount of
protein expressed from transfection of these three mutants in
NIH3T3 cells was variable, with the mutant LT-c/s exhibiting the
lowest level of expression (Figure 2D). However, it was clear that
the LT-delZ mutant, even with a high level of expression, did not
induce Necdin when compared to other mutants. The LT-c/s
mutant was able to reproduce the increase in Necdin expression
even with an overall lower protein level. The LT-CKII mutant
also showed similar increases in Necdin expression (Figure 2D).
These results suggest that Necdin expression is not directly
associated with the immortalization function of PyLT since the
mutation of PyLT affecting the modulation of Necdin expression
(LT-delZ), did not compromise its immortalization potential.
Necdin overexpression does not affect NIH3T3
proliferation in long term experiments
Necdin has been reported as a growth suppressor [26], and it is
counterintuitive that its expression would be stimulated by a viral
protein such as PyLT whose main function is to stimulate cell
cycling to promote viral DNA replication [9,42]. NIH3T3 and
PyLT-expressing NIH3T3 cells were thus compared. No differ-
ences in cell proliferation were observed (Figure 3A).
To further assess the effect of Necdin modulation in our model,
we used either gain or loss of function experiments. Three different
shRNAs (shNdn1–3) were transduced in NIH and NIHLT cell
populations resulting in decreased Necdin expression (Figure 3B).
Consistent with a role for Necdin as a growth suppressor,
removing Necdin expression by shRNA increased cellular
proliferation of NIH and NIHLT cell populations (Figure 3C
and 3D). Additionally, no cell death was observed in NIHLT cells
after Necdin removal indicating that its expression was not
necessary to maintain a PyLT-expressing cell population. While
NIH and NIHLT cells proliferate at the same rate, it remained
possible that Necdin levels were not elevated enough to cause
growth arrest in our cell lines. Therefore, we overexpressed
Necdin in NIH and NIHLT cells by using a lentiviral transduction
system (Figure 3E). A transient decrease in growth rate was
Figure 1. Validation of Affymetrix microarray data for selected genes in NIH3T3 and NIHLT clones. Northern blotting (using full-length
radiolabeled cDNA probes) was used to validate selected Affymetrix microarray patterns. Northern blots are compared to bar graphs representing
normalized microarray data. Stars represent the transcript corroborating microarray data when more then one band was detected by
autoradiography for a single probe. Note the lack of detectable PyLT in clone NIHLT33, although transcripts can be seen on longer exposures (data
not shown). There is no microarray data for the PyLT transcript. PyLT expression was verified on the total RNA used for microarray analysis.
doi:10.1371/journal.pone.0031916.g001
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previously shown by others [26]. However, maintaining these
populations for longer periods of time in culture rapidly allowed us
to derive populations that still expressed high levels of Necdin
without any growth defects (Figure 3F and Figure 3G). These
populations stably expressing Necdin were further characterized.
PyLT allows bypass of p53-dependent growth arrest
induced by nutlin-3
Necdin interacts with p53 and possibly modulates its activity
[35,39], which raises the possibility that PyLT exerts its inhibitory
effect on p53 through Necdin induction. Nutlin-3 is a small
molecule antagonist of MDM2, which prevents the interaction
between MDM2 and p53, thus promoting the accumulation of
p53 in cells [43]. It has been recently shown that nutlin-3 can
efficiently induce cell cycle arrest or apoptosis in different cancer
cell lines with functional p53 [44]. To assess the response induced
in our model, the NIH3T3 cell line was treated with nutlin-3 and
proliferation was followed by flow cytometry. Stimulation of NIH
cells with nutlin-3 resulted in the stabilization of p53 causing p21
induction (Figure S3A) and a gradual growth arrest (Figure 4A).
We did not detect apparent cell death as evaluated by the sub-G1
content (Figure 4B). When PyLT-expressing NIH3T3 cells were
treated with the same dose of nutlin-3, we observed an important
delay in growth arrest without a significant elevation in the amount
of cell death (Figure 4A and 4B). To confirm that growth arrest
obtained in our model was actually dependent on p53, we used a
dominant-negative p53 peptide, GSE22 [45,46], delivered by
lentivirus. As revealed by immunostaining, high infection efficien-
cies were reached with lentiviruses since almost all cells showed
expression of GSE22, which resulted in an accumulation of non-
functional p53 in the nucleus (Figure 4C). Inactivation of p53 by
GSE22 expression (NIH-GSE22) conferred almost complete
resistance to nutlin-3 (Figure 4D) thereby showing the p53-
dependence of nutlin-3 induced cell cycle arrest in NIH3T3 cells.
These results show that PyLT expression clearly protects against a
p53-dependent growth arrest, which supports previous reports on
the inhibitory activity of the viral protein on p53 [21,22].
p53-dependent growth arrest is delayed by Necdin
To address whether the presence of elevated Necdin levels in
PyLT expressing cells may play a role in the delayed p53-response,
Figure 2. Necdin as a relevant candidate. (A) Validation of the microarray identified Necdin gene by Northern blot analysis on an independent
extended clone set. Lanes 1 to 6 represent individual NIH3T3 sub-clones. Lanes 7 to 15 represent individual NIH3T3 clones transfected and selected to
express PyLT. Clones were independent from those used in the microarray analysis. DIG-labeled probes were used and exposure times were adjusted.
DOHX was used as a control. (B–C) Necdin protein level in (B) clones expressing variable level of PyLT or (C) additional heterogeneous populations of
NIH3T3 cells stably transfected with PyLT (NIHLT) or empty vector (NIH). (D) Different mutant forms of PyLT protein expressed in NIH3T3 were used to
determine the domain involved in Necdin modulation. Western blot shows protein expression levels. Representation of mutants utilized with Rb-
binding and immortalization capacity as reported previously [12,41].
doi:10.1371/journal.pone.0031916.g002
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cells where Necdin expression was decreased by the use of three
different shRNA (Figure 3B). In response to nutlin-3 treatment for
48 hours, an increase in cell cycle arrest was observed when
suppressing Necdin expression in NIHLT cells compared to
NIHLT infected with the control recombinant virus, shGFP
(Figure 5A). It was observed that shNdn 3, which repressed Necdin
less efficiently (Figure 3B), only showed a limited effect (Figure 5A).
Thus, the reduced presence of Necdin in NIHLT cells sensitized
them to p53 cell cycle arrest. We did not notice significant changes
using flow cytometry assays in NIH cells expressing shNdn
constructs presumably due to the fact that the parental cells
already expressed very low levels of Necdin, and were already
highly sensitive to cell cycle arrest (Figure S3B).
To validate these results, we also used Wst-1 assays to assess the
effect of Necdin loss on cell growth. Again, reduction of Necdin
levels by shRNA sensitized NIHLT to cell proliferation arrest
inducedbynutlin-3(Figure5B).Significant changeswhereobserved
for shNdn 1 and 2 at a dose of 10 mM while shNdn 3 did not vary
significantly.In all experiments,targetingNecdininNIHLTdidnot
convey the same sensitivity as NIH cells (Figure 5B). Unlike results
obtained using flow cytometry, reduction of Necdin levels in NIH
cells did sensitize them further to the p53-induced growth arrest
when measured using the Wst-1 assay (Figure S4C).
Conversely, Necdin overexpression delayed p53-mediated
growth arrest both in NIH and NIHLT as evaluated by DNA
content (Figure 5C). Consistent with flow cytometry, Wst-1 assays
revealed that the ectopic expression of Necdin appeared to
attenuate the effect of nutlin-3 in NIH and NIHLT (but only at the
5 mM concentration for NIHLT), although this reached statistical
significance only in NIH cells (Figure 5D). It should be noted that
the mere overexpression of Necdin did not confer to NIH cells the
equivalent response to nutlin-3 seen in the NIHLT cells (Figure 5C
and 5D). These results suggest that the acquired resistance to
growth arrest in PyLT-expressing NIH3T3 cells was in part
mediated by Necdin expression but also that other factors were
presumably involved. Nevertheless, Necdin could confer growth
arrest resistance even in the absence of PyLT.
Necdin is a p53-target gene induced by different
genotoxic stress
As shown in Figure 6A, a dose-dependent elevation of Necdin
protein levels in NIH and NIHLT cells were observed after
exposure to nutlin-3. This increase was also observed at the RNA
Figure 3. Necdin influences the proliferation of NIH and NIHLT populations. (A) NIH and NIHLT mixed populations proliferate at the same
rate. (B) Decrease of Necdin protein levels by three different shRNAs transduced by lentivirus infection in NIHLT and NIH. Growth curves for NIHLT (C)
and NIH (D) revealed that cells depleted in Necdin proliferate faster. (E) Protein expression level in NIHLT and NIH cells with overexpression of mouse
Necdin, the GFP control or vector alone. Growth curves for NIHLT (F) and NIH (G) expressing exogenous Necdin after a certain period of time did not
shown differences in their growth rate.
doi:10.1371/journal.pone.0031916.g003
Figure 4. Nutlin-3 induces a p53-dependent growth arrest in NIH3T3 cells that is bypassed by PyLT expression. (A–B) Flow cytometry
analysis of NIH or NIHLT populations treated with nutlin-3 (5 mM) demonstrate that nutlin-3 induces a growth arrest in NIH cells, but not in NIHLT
cells. Results presented are from one representative experiment (A) Cell cycle arrest was represented by the variation of ratio of arrested cells (G1+G2
phases) over proliferating cells (S phase) in treated cells versus untreated controls. (B) No variation of the percentage of cells in Sub-G1 phase,
representing cell death, was observed after nutlin-3 treatment. (C–D) The use of a p53 inhibitor peptide (GSE22) validates the p53-dependence of the
growth arrest induced by Nuclin-3. (C) High efficiency of infection and functionality of the GSE22 peptide were demonstrated by the accumulation of
non-functional p53 in the nucleus by immunocytochemistry detecting p53 in NIH transduced with GSE22 or control vector. The stabilization of non-
functional p53 was also seen in Western blots of the corresponding infected cells. (D) FACS analysis on NIH transduced with GSE22 or vector with
nutlin-3 treatment (*P,0.05, **P,0.01 t-test).
doi:10.1371/journal.pone.0031916.g004
PyLT/Necdin Affects p53 Response
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!?tlsb=-.005w?>rather than a protein stabilization. This transcrip-
tional regulation was p53-dependent since inactivation of p53 with
GSE22 peptide abolished the Necdin increase seen in response to
nutlin-3 stimulation (Figure S4C). This is consistent with a recent
report suggesting that Necdin is a direct target gene of p53[36]. We
then examined if other genotoxics stresses known to induce p53
could also cause Necdin upregulation. Both Camptothecin, a
Topoisomerase I inhibitor, and Actinomycin D, an inhibitor of
transcription, are known to induce p53 activation [47]. Increased
Necdin expression levels were observed in all cells treated with
these two drugs (Figure 6B). By extension, this suggests that Necdin
is a part of p53 pathways that can be induced by different signals.
Necdin upregulation in PyLT-expressing cells is
independent of p53
Since p53 activation induces Necdin expression, we hypothe-
sized that the PyLT-mediated induction of Necdin may involve an
increase in p53 basal activity in NIHLT cells. To assess p53
involvement, the p53 inhibitor GSE22 was introduced in NIHLT
Figure 5. Necdin confers resistance to p53-dependent growth arrest. (A–B) NIHLT cells depleted in Necdin by shRNAs and exposed to nutlin-
3 showed an increase in growth arrest (A) measured by DNA content analysis by flow cytometry (as described in figure 4A) or (B) assessed by Wst-1
colorimetric assay. Results for Wst-1 represent normalized data according to the portion of arrested cells (O.D. untreated – O.D. treated) relative to
arrested control NIH after 48 h of exposure to nutlin-3. (C–D) NIH and NIHLT cells overexpressing Necdin showed growth arrest resistance upon
nutlin-3 treatment. (C) FACS analysis or (D) Wst-1 colorimetric assay (*P,0.05, **P,0.01 t-test).
doi:10.1371/journal.pone.0031916.g005
PyLT/Necdin Affects p53 Response
PLoS ONE | www.plosone.org 7 February 2012 | Volume 7 | Issue 2 | e31916cells and changes in p53-induced gene expression were analyzed.
Expression of GSE22 affected basal mRNA of p53 target genes as
judged by the level of p21 (2.5-fold decrease) but did not affect the
control GAPDH (Figure 6C). In the same extract, the Necdin level
was not affected by inhibition of the p53 function (Figure 6C).
These data demonstrate that although Necdin is induced by p53 in
response to cellular stresses, PyLT does not require p53 to mediate
increased Necdin expression levels.
Necdin is expressed in low malignant potential ovarian
cancer
Since Necdin expression can be regulated independently of p53
and canrepressp53activity,itispossible that deregulation of Necdin
may be important in cancers with wild type p53, where Necdin may
play a role in inhibiting the p53 tumor suppressor activity. To test
this, we examined Necdin expression in low malignancy potential
(LMPs) versus aggressive ovarian cancer (TOVs), two distinct types
of serous ovarian cancer thought to have different molecular origins,
and where p53 mutations rarely (in LMPs) or frequently (in TOVs)
occur [48,49]. A set of seven LMP and eight TOV tissues were used
and Necdin mRNA levels were determined by quantitative real-time
PCR analysis. The relative expression levels revealed a significant
difference in Necdin expression (P,0.0001) between tissues from
LMPand TOV,withhigherlevelsfoundinLMPtissues(meanvalue
was .10-fold higher) (Figure 7).
Discussion
Genes regulated by PyLT were identified in a mouse
fibroblast cell culture model. Considering that PyLT has anti-
apoptotic activities [18], that it maintains strong homologies in
essential domains to the transforming oncogenes SV40LT and
E1A [7], and that its expression in transgenic mice leads to
tumors development [15,16], it was hypothesized that these
PyLT structure-function properties could provide clues to early
steps during the transformation process. Since NIH3T3 cells
were already immortalized mostly through the biallelic deletion
of the INK4 locus [50,51], PyLT-mediated immortalization
was not a selection criteria in our model and we considered
candidate genes as possibly immortalization-independent.
Figure 6. PyLT-induced Necdin expression is p53-independent. Necdin is induced following activation of p53. (A) Dose response treatment
with nutlin-3 increased Necdin protein level in NIH (left) and NIHLT (right). (B) Genotoxic stress induced by Actinomycin D and Camptothecin also
stimulated Necdin protein expression. (C) In NIHLT cells, Necdin expression is not dependent on p53 activity as assessed by p53 inhibition. Mean of
relative expression of Necdin, p21, p53 and GAPDH in NIHLT cells with or without the p53 inhibitor GSE22. Expression was measured by Q-PCR in
three independent samples from each group. Expression is relative to actin (**P,0.001, t-test).
doi:10.1371/journal.pone.0031916.g006
PyLT/Necdin Affects p53 Response
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mation-associated candidate genes that corroborates the existing
literature and point out the importance of viral proteins as tools to
identify events related to cancer progression. For example,
Transgelin, an actin-binding protein downregulated in our study,
is also downregulated in virally transformed human cells and in
human breast, colon and lung cancers [52,53]. Alternatively, DNA
methyltransferase 1 (Dnmt1), which contributes to the mainte-
nance of tumor suppressors silencing in colon cancer progression
and in tumorigenic cell lines [54,55], is also upregulated by PyLT
expression. Importantly, Dmnt1 is recognized as a significant
event during the carcinogenesis process in models related to
polyomavirus T antigen expression including the prostate cancer
mouse model expressing SV40LT (TRAMP) [56], and transfor-
mation of cell lines by SV40LT or the human polyomavirus BKV
[57,58]. Interestingly our main candidate gene, Necdin, was also
upregulated in a mouse prostate cancer progression model based
on SV40LT expression [59]. Initial observations for Necdin
expression in human cancer suggested a tumor suppressor function
due to its lack of expression in brain tumor cell lines [25], its
decrease in melanomas [60], and in bladder cancer cell lines and
tumors [61]. Conversely, more recent studies revealed loss of
imprinting and upregulation of Necdin in pancreatic cancer
[62,63]. As a whole, Necdin function in cancer remains poorly
defined and warrants further investigation.
Identification of functional activities associated with PyLT
One way to identify closely interacting proteins (physical or
functional associations) is to monitor their mRNA expression levels
since they are often co-regulated [40]. Since the group of genes
shown in Table S2 most closely correlates with PyLT expression at
the transcriptional level, these genes represent good candidates for
functional associations. One particularly promising member of this
group is Necdin, whose gene product has Rb-like growth
regulatory activities and has been shown to interact with p53
and viral oncogenes such as SV40LT and E1A [32,35]. It has been
hypothesized that the Rb-like activity of Necdin leads to cell
growth arrest when overexpressed in neurons and fibroblasts
[26,32]. In particular, the growth inhibitory effects of Necdin were
described in a model system using NIH3T3 cells [26]. Here, we
demonstrate that PyLT expression in NIH3T3 cells results in
increases in both Necdin transcript and protein levels but without
altering the long-term growth of PyLT-expressing cells. This
suggests that PyLT can inhibit the known growth suppressive
functions of Necdin [26]. Surprisingly, continued proliferation in
the presence of high levels of Necdin was not due to the
simultaneous expression of PyLT since the overexpression of
Necdin alone produced long-term Necdin-expressing NIH3T3
cells. Indeed, cell growth slowed immediately following Necdin
expression, as previously described [26], but as shown in this
study, the cells rapidly recovered and maintained normal
proliferation rates while maintaining high Necdin levels. This
divergence in Necdin-influenced cell proliferation may be
explained by differences between the experimental approaches.
Although the previous study also used the mouse Ndn sequence,
the protein was conditionally expressed in NIH3T3 cells with an
inducible expression system. Three independent clones were
selected and analyzed immediately after induction. In contrast,
we used lentivirus-mediated Necdin expression and evaluated the
growth potential of heterogeneous populations after a period of
selection and some passages in culture. While long-term Necdin
overexpression was not incompatible with cell growth, we cannot
yet conclude whether the emerging population came from a
selective pressure for cells able to tolerate high Necdin expression
or if they came from a transient anti-proliferative effect of Necdin
from which most cells can adapt. Interestingly, we also ex-
perienced difficulty with the production of recombinant lentivi-
ruses from Necdin constructs (also reported by [32]), potentially
reflecting Necdin related growth inhibition in the packaging cell
line 293FT.
Necdin regulation by PyLT-Ag
The increase in Necdin expression in response to PyLT
expression was not caused by Rb inactivation but was dependent
on the presence of the PyLT C-terminal zinc finger domain. This
PyLT domain is required for viral DNA replication possibly due to
its involvement in protein-protein interaction, which allows the
formation of PyLT hexamers [64]. Given that the zinc finger motif
is conserved in several polyomavirus large T antigens, this supports
the idea that other large T antigens may also induce Necdin
expression. Although mutations in this domain do not abolish the
immortalization property of PyLT [41], deletions in this domain of
SV40LT or papillomavirus E7 decreased their transforming
potential [65,66]. Accordingly, Necdin could have a potential
role in the transformation process involving viral proteins but not
in immortalization. Necdin induction by PyLT could arise through
direct PyLT interaction with DNA or with cellular transcription
factors via its zinc finger domain to enhance their activity at the
Necdin promoter. One promising candidate is Lim domain only 4
(LMO4) known to control the expression of the Ndn gene [67] and
that was also upregulated following PyLT expression (Table S2).
LMO4 demonstrates variable expression in different cancers but
its role remains unclear since in breast cancer, high LMO4
expression is associated with a poor prognosis [68,69], while in
pancreatic cancer it is associated with a better survival [70,71].
The p53-Necdin negative feedback loop
Necdin was identified in our screen using conditions that high-
light stable events occuring in continuously proliferating cells.
These conditions presumably reflect the plasticity of heteroge-
neous cancer tissue where each cell will not have the exact same
fate upon exposure to stress and where selection pressures allow the
emergence of growth/survival promoting properties. According to
Figure 7. Necdin expression is detected in LMP and is lower in
TOV. Q-PCR analysis of tissues from seven LMP serous ovarian cancers
and eight high grade serous ovarian cancers. Expression of Necdin gene
(P,0.0001, Mann-Whitney’s U test) relative to ERK-1.
doi:10.1371/journal.pone.0031916.g007
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would be beneficial for a cell to lose Necdin expression to acquire a
proliferative advantage, unless maintaining Necdin was somehow
advantageous to the cancer cell. Therefore, we examined whether
in some contexts, increased Necdin could paradoxically promote
growth or survival.
A possible role for Necdin in DNA damage response was
suggested by the upregulation of Necdin following different
genotoxic stresses. By using nutlin-3, we showed that p53
activation clearly induced Necdin in a dose dependent manner,
supporting a previous report that identified Necdin as a p53 target
gene [36]. Moreover, we show that modulation of the Necdin level
affects p53-dependent growth arrest. Indeed, we demonstrate that
an increase in Necdin expression results in a delayed cell cycle
arrest while inversely targeting Necdin by shRNA accelerates this
arrest. The interaction of Necdin with p53 [35] suggests that this
delay in growth arrest is probably associated with a direct
inhibitory effect of Necdin over p53. We noted that Necdin
affected p21 induction following p53 activation in our model
(Figure S3D and S3E) supporting previous results [35]. Therefore,
interference with p53 transcriptional activity may represent the
mechanism underlying the cell cycle arrest variations caused by
Necdin. However, we believe that other mechanisms may be
involved since p21 mediated-arrest mostly relies on functional Rb
[72,73] and in PyLT-expressing cells, the Rb proteins are kept
inactive by their interaction with PyLT [74,75].
As p53 induction upon genotoxic stress is associated with
multiple additional signaling events, we directly addressed p53
stimulation by exposure to nutlin-3. This specific stimulation
results in a functional induction of p53, although the post-
translational phosphorylation of p53 observed with genotoxic
stress are absent or barely detectable with nutlin-3 [76,77]. This
suggests that phosphorylation may not be critical for interaction of
Necdin with p53 and that Necdin does not interfere with the
phosphorylation status to modulate p53 activity. In addition to
phosphorylation, other modifications contribute to p53 activity
[78], including acetylation, which is increased upon nutlin-3
stimulation [79]. The deacetylase Sirt1 is a negative regulator of
p53 activation [80,81] and Necdin interactions with this protein
potentiate its activity upon genotoxic stress [39]. However, we did
not address the status of these post-translationals modifications in
our model. Additionally, it is important to note that p53 responses
can differ with particular drugs depending on the dose employed,
the duration of the treatment, and the metabolic state of the cell
[82,83].
Others mechanisms can explain Necdin inhibitory effects over
p53. Necdin binds the N-terminal transactivation domain of p53
[35]. Some proteins share this binding site, among them SOCS1,
which contribute to p53 activation [84]. It is possible that Necdin
competes with activating proteins such as SOCS1 for p53 binding,
leading to a decrease in p53 response. Others examples exist
where the response to p53 activation varies according to the
presence or absence of specific cellular partners. The capacity of
p53 to translocate to the mitochondria where it plays a
transcription-independent function in apoptosis is now well
documented. Tid1 is a p53-interacting protein that helps this
localization from the nucleus to mitochondria [85]. Both
cytoplasmic and nuclear cellular partners have been revealed for
Necdin and expression of these partners has been shown to cause
Necdin relocalisation in the cell [28,86,87,88,89]. Perhaps
interference with p53 activation may arise from the ability of
Necdin to relocate p53 in other cellular compartment. All these
mechanisms are consistent with the notion that Necdin can inhibit
p53 function and require further investigation.
Combining our data on p53 inhibition by Necdin with the
knowledge that Necdin is a direct p53 response gene suggests that
Necdin is part of a negative feedback loop controlling p53 activity.
Under normal conditions, this loop is probably well controlled and
allows normal regulation of cellular responses as in the case of the
p53 negative regulator and target gene mdm2 [90,91]. Impor-
tantly, our results also show that Necdin can be induced by PyLT
in a p53-independent manner, which, in a cancer context, could
cause a reduction in p53 activity and potentially contribute to
checkpoint bypass and genomic instability [92].
Necdin is expressed in the borderline ovarian cancer
subtype
According to the literature, Necdin expression may not be
suitable for tumor progression. Necdin has an anti-angiogenic
function by interacting with HIF-1-alpha and by negatively
regulating its activity on VEGF induction [93,94]. VEGF play a
major role in the proliferation and migration of endothelial cells,
thereby nourishing and favoring tumor growth by a pro-
angiogenic function. Moreover, Crawford and al. [95] identified
some genes predictive of metastasis in breast cancer from a
quantitative trait locus analysis and found Necdin among their
candidates whose expression diminished with increased risk of
metastasis. These results evoke a possible limited capacity of tumor
progression to an advance stage in the presence of Necdin
expression. In this study, we chose to further characterize Necdin
in ovarian cancer since this pathology includes a particular subset
of low malignancy cancer. LMPs are non-invasive, or only display
micro-invasion, rarely progress to an aggressive metastatic cancer
and patients with LMP disease have a 5 years survival rate of 95%.
Here, we observed higher expression of Necdin in LMPs
compared to TOVs. In line with this, LMPs have low angiogenesis
as compared to TOVs [96], which fits nicely with Necdin’s anti-
angiogenic activity.
Moreover, LMP rarely have mutation in TP53 while 50 to 80%
of high-grade carcinomas present abnormalities in TP53 [48,49].
This could indicate that in LMPs, where p53 is wild type,
alternative mechanisms are responsible to render p53 inactive.
Our results revealed an inhibiting function of Necdin over p53-
dependent growth arrest. Therefore, Necdin expression in LMPs
may attenuate the response when p53 activity is required. Taken
together, the data support the notion that in ovarian cancer,
Necdin expression correlates with a favorable prognosis. The
hypothesis that LMP tumors are precursors of invasive tumors is
still controversial, but the evidence suggests that they are two
distinct diseases. Expression of Necdin in borderline ovarian
tumors could be characteristic of this particular ovarian cancer
and may have a biologic impact on p53 pathways and malignancy.
However, these possible functions require more investigation.
Conclusion
While the temporal order of multi-step carcinogenesis events
may not be crucial, especially since immortalization and trans-
formation are in vitro concepts, the pathways or genes themselves
may point to important parameters during carcinogenesis. It is
likely that some of the candidate genes identified here may play a
role in human cancer. Our results suggest that Necdin harbors
both tumor suppressive or oncogenic properties depending on the
cellular context. These oncogenic properties were demonstrated
here by the inhibitory effect of Necdin over p53-mediated growth
arrest and by others where Necdin contributed to p53-induced
apoptosis resistance [35,39]. In combination with Necdin
expression patterns during ovarian cancer progression, these
results warrant further investigation about the context-dependent
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vestigating the functional significance of the identified candidates
during multistep carcinogenesis.
Materials and Methods
Ethics Statement
T h eC e n t r eh o s p i t a l i e rd el ’ U n i v e r s i t e ´d eM o n t r e ´al (CHUM)
institutional ethicscommittee approved the ovarian tumorsstudyand
written consent was obtained from patients prior to samplecollection.
Cell culture
NIH3T3 cell lines [97] were purchased from ATCC. All cell
lines were cultured in Dulbecco’s modified Eagle’s media (DMEM)
supplemented with 10% fetal bovine serum, gentamycin and
amphotericin. Cells were grown at 37uC with 5% CO2 and kept at
low-density conditions to prevent culture induced transformation
[97,98]. For proliferation experiments, 5610
4 cells were seeded in
6 well plates and the number of living cells determined using the
CASYH cell counter model TT or by a hematocytometer.
Experiments were repeated at least three times in duplicate.
For p53 stimulation, the following reagents was used: Nutlin-3
(5–20 mM), Actinomycin D (60 mM) and Camptothecin (5 mM).
Vectors and transfections
The PGKLTneo plasmid was constructed by introducing
Neomycin resistance from the pSV2neo vector into PGKLT [18]
and was used to transfect NIH3T3 cells. The PGKLTGFPneo
vector was generated by cloning eGFP from Clontech eGFP-N1
vector in frame with PyLT into PGKLTneo. A small C-terminal
deletion of PyLT was introduced encompassing amino acids 685–
785. All stable clones were selected with 0.5 mg/ml G418 applied
48 hrs post-transfection and named ‘‘LT’’ follow by a different
number representing each independent clone. Heterogeneous
populations expressing PGKLTneo plasmid or the control vector
PGKN were generated with Lipofectamine 2000 transfection
reagent (Invitrogen). We referred to these heterogeneous popula-
tions as NIHLT and NIH respectively. Mutant forms of PyLT are
described elsewhere [12,41]. Briefly, LT c/s contain a cysteine to
serine substitution in amino acid 144. In LT CKII, some amino
acids in the phosphorylation motif adjacent to the Rb binding motif
were substituted to mimic an E7 CKII motif. LT delZ contains a
deletion in amino acids 452 to 469 in the zinc finger domain.
Lentiviral constructs and infections
Mouse Ndn was PCR amplified from a Riken clone (clone
1500000G13) followed by insertion in pENTR/D-TOPOH (In-
vitrogen). The generated pENTR-ndn vector was recombined in
the 670-1 vector (pLenti CMV/TO Puro DEST, Addgene 17293)
[99] using recombination cloning technology from Invitrogen.
Empty control vector (referred to as Vector in figures) was the
product of 686-1 (pENTR4 no ccDB, Addgene number17424)[99]
recombined with the 670-1 vector. eGFP and GSE22 (encoding an
interfering p53 fragment) are described elsewhere [45,100]. For
gene repression, pLKO.1 lentiviral shRNA vectors targeting the
mouse Ndn gene were purchased from Open Biosystems: shNdn1
(TRCN0000103780), shNdn2 (TRCN0000103781), shNdn3
(TRCN0000103782). shGFP from Open Biosystems (RHS4459)
was used as control vector. The Virapower lentivirus expression
system (Invitrogen) allowed us to deliver genes of interest or shRNA
in mixed populations (NIH and NIHLT). Briefly, the vector of
interest was cotransfected with a packaging mix in 293FT. The
supernatant was collected after three days and was either used fresh
or concentrated. Infections were done overnight in the presence of
polybrene, and puromycin selection was applied 48 hrs later.
RNA and Proteins extractions
RNA was extracted directly from 80% confluent 100 mm petri
dishes with TRIzol
TM reagent (Gibco/BRL, Life Technologies
Inc.). RNAs used in microarray experiments were further purified
with QIAGEN Rneasy columns. Total proteins were extracted
from 80% confluent 100 mm plates in buffer containing: 50 mM
Tris HCl, pH 7.4, 150 mM NaCl, 1 mM EDTA, 1% TRITON|
X-100, protease inhibitor Cocktail (Complete Protease Inhibitor
cocktail Tablets, Roche), NaF and NaOV.
Microarray analysis
Biotinylated hybridization targets were prepared from total RNA
as described [101]. Affymetrix arrays Mu74a were used in
experiment 1 to hybridize cRNA from the parental NIH3T3
population and from clones NIHLT11, NIHLT47, NIHLT40,
NIHLT50. Arrays Mu74a2 were used in experiment 2 to hybridize
NIHcM, an untransfected NIH3T3 sub-clone, and clones NIHLT7,
NIHLT12, NIHLT32, NIHLT33, NIHLT46, and NIHLTGFPA
(expressing a PyLT eGFP fusion protein). Gene expression levels
were calculated for each EST from the scanned image by the
Affymetrix GeneChip software algorithm. After normalization to the
total average intensity, all probe sets whose expression levels were
below 50 were raised to 50. The ,25% of probes on the Mu74a
arrays corresponding to Affymetrix synthesis errors were removed
from both experiments for subsequent analysis. Based on data
acquired by Northern blots analysis, individual microarray datasets
were pooled into two groups, a first group containing samples with
clearly detectable PyLT expression (NIHLT11, NIHLT32,
NIHLT40, NIHLT46, NIHLT47, and NIHLT50), and a second
group of samples lacking PyLT expression (NIH3T3, NIHcM,
NIHLT7, and NIHLT12). Groups were compared against each
othertodetectsignificantdifferencesingeneexpression(Foldchange
of more than 50% increase/decrease at a P value of 0.02 or better,
see Table S1). The candidate genes modulated at the transcriptional
level by PyLT were reordered using GENESPRING
TM to identify a
group of genes that have an expression pattern closely matching
PyLT expression levels (Table S2).
Candidate gene expression validation
Northern blot analysis has been described elsewhere [18].
Radiolabeled probes were generated from RIKEN full-length
cDNA. A subset of Northern blots were hybridized and revealed
using Dig-labeled 1 kb cDNA probes according to the manufac-
turer’s instructions (ROCHE Diagnostics).
Western blotting and immunocytochemistry
The following antibodies were used for western blotting: Necdin
(07-565), GFP (JL-8, 8371-2), p21 (F-5, sc-6246), p53 (Ab-1, clone
PAb-240), HSP60 (N-20, sc-1052), Actin (AC-15, ab6276). The
polyclonal antibody specific to PyLT (Mm1a) was produced by
injection of PyB4a to form ascites in BN rat cells [102]. All HRP-
conjugated secondary antibodies were purchased from Santa
Cruz. Immunocytochemistry was performed on formaldehyde
fixed cells with the DakoCytomation kit according to the
manufacturer’s protocol. p53 Pab240 antibody was used to detect
non-functional p53 in the native form.
Cell cycle analysis and proliferation
For p53 activation, 5 mMo r1 0mM of nutlin-3 (Sigma) was
used, with DMSO being used for untreated control. Flow
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profiles. Approximately 1610
5 cells were seeded in 6-well plates
and treated 24 hours later for the indicated period of time. Cells
and medium were collected and centrifuged. Cells were fixed and
stained with propidium iodide. The use of nutlin-3 mimics the
overexpression of p53 as it causes the release of p53 from mdm2,
which results in its accumulation [43]. Nutlin-3, like p53
overexpression, has been described to induce growth arrest in
both the G1 and G2 phase [103,104,105]. Accordingly, we present
FACS data as a ratio of arrested cells (G1+G2 phases) over
proliferating cells (S phase). Cell proliferation reagent WST-1
(Roche) was used to follow growth arrest in NIH and NIHLT
treated with nutlin-3. 5610
3 cells were plated in 96-well plates
and treated 24 hrs later for a period of 48 hrs. Growth arrest is
the difference between proliferation of untreated cells and
proliferation of treated cells (O.D. untreated – O.D. treated).
This result was normalized to growth arrest with the internal
control NIH.
Quantitative Real-Time PCR
Total RNA was extracted with TRIzolH reagent as described by
the manufacturer and the quantity and quality were determined
with the Agilent 2100 Bioanalyzer and NanoDrop. cDNA was
generated using the QuantiTectH Reverse Transcription Kit
(Qiagen). For Q-PCR, SYBR Green PCR Master Mix (Qiagen)
was used for cDNA labeling and was performed with the Rotor-
Gene 3000 Real-Time PCR Detection System (Corbett Life
Sciences). The Pfaffl analysis method [106] was applied to data
generated by Q-PCR. Primer sequences were from RTprimerDB
[107] and are available upon request. For the ovarian cancers
study, tumor samples were collected through the Division of
Gynecologic Oncology at the Centre hospitalier de l’Universite ´d e
Montre ´al (Ho ˆpital Notre-Dame). We focused on samples of serous
histopathology obtained from chemotherapy naı ¨ve patients.
Experiments on ovarian tumor tissues were done twice in
duplicate for each sample. Comparative gene expression analysis
in ovarian samples was performed using ERK1 as an internal
control based on previous results [108].
Supporting Information
Table S1 Microarrays analysis containing 194 genes
modulated by PyLT expression in NIH3T3 (1,5 folds,
P#0.02).
(XLS)
Table S2 PyLT-mediated changes in gene expression
profile in NIH3T3 cells. A partial listing of PyLT modulated
genes representing candidates whose expression variation corre-
lates with the level of PyLT mRNA.
(XLS)
Figure S1 PyLT expression and candidates selection. (A)
Western blot analysis of PyLT expression in selected clones used
for microarrays analysis. The PyLT row represents the expression
levels of PyLT protein in all clones (note that like the mRNA in
Figure 1, PyLT protein in clone NIHLT33 is only detected on
long exposures). (B) Genespring software representation of gene
expression from candidates whose expression correlates with the
level of PyLT, with emphasis on Necdin expression. PyLT mRNA
expression levels by Northern blot analysis are presented below.
(TIF)
Figure S2 Necdin induces growth arrest in short term
experiment. Overexpression of Necdin caused growth inhibition
in three different experiments (A) Proliferation curve of NIH and
NIHLT cells two weeks after transduction with Necdin or control
vector. (B) Cellular proliferation assessed by colorimetric BrdU
ELISA Kit (ROCHE) in the same population. (C) Proliferation
monitored by Wst-1 assays on NIH3T3 cells transiently transfect-
ed with Necdin or control vector.
(TIF)
Figure S3 Effects of Nutlin-3 stimulation in NIH
population. (A) Nutlin-3 stimulation of NIH cells induced an
increase in p53 protein levels accompanied by an increase of its
target gene p21 (B) Flow cytometry analysis of NIH and NIH
shNdn1 to 3 treated with nutlin-3 showed no significant variation
in growth arrest. (C) Wst-1 colorimetric essay on the same
populations after 48 hrs of nutlin-3 treatment revealed increased
sensitivity to growth arrest in Necdin-depleted NIH cells. Graph
represents differences between treated and untreated cells
normalized according to NIH control. (** P,0.01, t-test) (D) Q-
PCR for p21 expression upon nutlin-3 stimulation (24 hrs) or
control DMSO, in NIH and NIHLT cells overexpressing Necdin
or Vector. (E) Protein levels in NIHLT cells containing shNdn or
control 48 hrs after nutlin-3 stimulation.
(TIF)
Figure S4 Nutlin-3 stimulation of NIH and NIHLT
populations induces Necdin mRNA in a p53-dependent
manner. (A–B) Necdin was induced in a dose-dependent manner
with nutlin-3 treatment in (A) NIH and (B) NIHLT. (C)
Inactivation of p53 by transduction of NIH with GSE22 inhibited
Necdin induction by nutlin-3. Relative expression by Q-PCR
analysis according to GAPDH.
(TIF)
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